Our Podcast
MDS Professional Report
This podcast series provides important up-to-the-minute information on MDS including diagnosis, treatment and clinical research. The explosion of information on MDS forces us to seek novel, alternative ways to distribute it. Podcasts gives us an easy and popular way to communicate this information in a short time.
![Treatment of lower-risk MDS [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_160/images.spreaker.com/original/59731ffad6896313dd70ce957e619b02.jpg)
December 15, 2024
4. Treatment of lower-risk MDS [MDS Professional Report]
Prof. Uwe Platzbecker from Leipzig and Prof. Moshe Mittelman from Tel-Aviv in an interesting conversation on the various available therapeutic modalities for patients with lower-risk MDS.
![Treatment for Higher-risk MDS [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_160/images.spreaker.com/original/474af5f93a7c919181979937a2ea20a4.jpg)
December 1, 2024
3. Treatment for Higher-risk MDS [MDS Professional Report]
Prof. Nicolaus Kröger from Hamburg and Prof. Moshe Mittelman from Tel-Aviv, in a stimulating conversation on the various therapeutic modalities, including hematopoietic transplantation, in patients with higher-risk MDS.
![Update on Higher-Risk MDS - Lessons from 2023 ASH [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_160/images.spreaker.com/original/6fb86eb9669a4d2de76fbe628d3c3231.jpg)
May 27, 2024
2. Update on Higher-Risk MDS - Lessons from 2023 ASH [MDS Professional Report]
Dr. Nicolaos Papadantonakis from Emory Atlanta and Dr. Moshe Mittelman from Tel-Aviv, describe several updated abstracts from 2023 ASH with a special focus on Higher-risk MDs, and providing their take home messages.
March 27, 2024
1. New trials to address the anemia of lower-risk MDS [MDS Professional Report]
Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss trials presented in American Society of Hematology (ASH) 2023 meeting. They provide some data on luspatercept, imetelstat, roxodustat and Ker-050.
